Frexalimab (SAR441344) is a second-generation humanized monoclonal antibody targeting CD40L. It blocks the CD40/CD40L signaling pathway to reduce inflammation and tissue damage, making it applicable for autoimmune diseases such as primary Sjögrens syndrome, systemic lupus erythematosus, and multiple sclerosis.
Purity:
95.00%
CAS Number:
[2515463-86-0]
Target:
Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted
